Intratumoral G100, a TLR4 agonist, induces anti-tumor immune responses and tumor regression in patients with Merkel cell carcinoma.

CONCLUSIONS: In this first-in-human study, IT G100 induced anti-tumor immune responses, demonstrated acceptable safety, and showed encouraging clinical activity.
PMID: 30093453 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 9, 2018 Category: Cancer & Oncology Authors: Bhatia S, Miller NJ, Lu H, Vandeven NV, Ibrani D, Shinohara M, Byrd D, Parvathaneni U, Kulikauskas RM, Ter Meulen J, Hsu FJ, Koelle DM, Nghiem P Tags: Clin Cancer Res Source Type: research